Aramis Biosciences
is a Private company. David S. Tierney is the President & CEO of Aramis Biosciences. Aramis Biosciences has received a total of $10.5M in funding. Aramis Biosciences has 1 followers on Owler. Aramis Biosciences has an estimated revenue of <$1M and an estimate of less <10 employees.Aramis Biosciences
is a Private company. David S. Tierney is the President & CEO of Aramis Biosciences. Aramis Biosciences has received a total of $10.5M in funding. Aramis Biosciences has 1 followers on Owler. Aramis Biosciences has an estimated revenue of <$1M and an estimate of less <10 employees.
News
Nov 03, 2022
GlobalNewswire
Press Release: Aramis Biosciences : Aramis Biosciences Completes Enrollment of its Phase II Clinical Trial Evaluating A197 for the Treatment of Dry Eye Disease
Feb 28, 2022
FirstWord Pharma
Aramis Biosciences: Aramis Biosciences Announces First Patient Dosed in Phase II Clinical Trial Evaluating A197 for the Treatment of Dry Eye Disease
Jan 11, 2022
GlobalNewswire
Press Release: Aramis Biosciences : Aramis Biosciences Announces FDA Clearance of IND Application for A197, a Novel Immunomodulatory Agent for the Treatment of Dry Eye Disease
Dec 16, 2021
firstword pharma
Aramis Biosciences: Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunology